Moderna Targets New Vaccine, Oncology, and Rare Disease Launches Through 2028

Moderna is preparing for a significant portfolio expansion, with up to three new product launches anticipated in 2027–2028 and several late‑stage programs approaching pivotal milestones. The company is evolving from a vaccine‑focused biotechnology firm into a diversified developer of infectious disease, oncology, and rare disease therapies.

Three Vaccine Launches in 2027–2028

Building on a commercial portfolio of four approved products, Moderna expects potential launches of three investigational vaccines: a flu‑COVID combination candidate, a standalone seasonal influenza vaccine, and a norovirus vaccine. Regulatory submissions are anticipated beginning in 2027.

These launches would broaden Moderna’s infectious disease franchise, reduce reliance on COVID‑19 revenue, and strengthen its position in the global respiratory and seasonal vaccine markets.

The programs will enter competitive markets dominated by Pfizer, GSK, and Sanofi, underscoring the importance of differentiation in efficacy and durability.

Oncology and Rare Disease Milestones

Beyond vaccines, Moderna expects pivotal data in 2026 from two of its most advanced therapeutic programs. Intismeran autogene, an individualized neoantigen therapy, is designed to generate patient‑specific immune responses against tumor mutations. Positive Phase 3 results could support Moderna’s first oncology launch.

In rare diseases, the company’s investigational therapy for propionic acidemia uses mRNA to encode functional propionyl‑CoA carboxylase, directly addressing the enzyme deficiency underlying this life‑threatening metabolic disorder. Success in either program would mark a major milestone by extending mRNA technology into therapeutic applications.

Expanding mRNA Beyond Vaccines

Moderna’s pipeline now spans oncology, rare genetic disorders, latent viruses, respiratory diseases, and next‑generation vaccine platforms. By leveraging mRNA’s ability to instruct cells to produce specific proteins, the company aims to address a wide range of conditions through both preventive and therapeutic approaches. This strategy reflects a deliberate effort to establish mRNA as a versatile modality across multiple disease areas.

Leadership Aligned with Growth

To support its expanding portfolio, President Stephen Hoge, M.D., will assume broader operational oversight across R&D, manufacturing, and commercial functions spanning infectious disease, oncology, and rare disease franchises.

Moderna also appointed Ester Banque as Chief Commercial Officer, bringing experience from Zoetis, Bristol Myers Squibb, and Novartis, where she oversaw multiple launches in oncology, hematology, and specialty medicine.

CEO Stéphane Bancel emphasized that the changes are designed to strengthen execution as Moderna approaches multiple launches and late‑stage milestones.

Path Forward

The next 24 months could represent one of the most consequential periods in Moderna’s history. Regulatory submissions and potential launches for respiratory vaccines may expand its commercial footprint, while pivotal oncology and rare disease data could open entirely new therapeutic markets.

Alongside these programs, Moderna continues to invest in Moderna Research and Early Development (mRED), its discovery engine for advancing new mRNA modalities. If successful, these efforts could establish mRNA as a therapeutic platform beyond vaccines, reshaping Moderna’s trajectory well into the next decade.

Reference

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028